Mar 28, 2017 | News
RESEARCH TRIANGLE PARK, NC (PRWEB) MARCH 28, 2017 – T3D Therapeutics, Inc., a clinical stage drug development company engaged in the development of a new orally administered treatment for Alzheimer’s disease (AD), today announced that Dr. Kathleen Welsh-Bohmer...
Dec 1, 2016 | News
Research Triangle Park, NC (PRWEB) November 30, 2016 — T3D Therapeutics, Inc., a clinical stage drug development company engaged in the development of a new orally administered treatment for Alzheimer’s disease (AD), today announced that CEO, John Didsbury, will...
Aug 3, 2016 | News
T3D Therapeutics, Inc., a clinical stage drug development company engaged in the development of a new orally administered treatment for Alzheimer’s disease (AD), today announced that preliminary Phase 2a data with T3D-959 in mild to moderate Alzheimer’s disease...
Jul 21, 2016 | News
On Wednesday, July 27th in Toronto, T3D Therapeutics will present Preliminary Results of a 36-patient, two-week Phase 2a Open Label Feasibility Clinical Trial, showing Rapid Onset of Cognitive Improvements in a Subset of Mild and Moderate Alzheimer’s Patients Treated...
Jun 23, 2016 | News
T3D Therapeutics has received FDA approval for an open-label, 26-week extension study in mild to moderate Alzheimer’s disease patients extending its Phase 2a feasibility study of T3D-959, an investigational new drug candidate that has the potential to be...
Jun 8, 2016 | News
T3D Therapeutics, Inc. has achieved a significant clinical trial milestone in its Phase 2a feasibility study in mild to moderate Alzheimer’s disease patients with T3D-959, an investigational new drug candidate that has the potential to be transformative by slowing,...
